Skip to main content

Table 2 Adverse events reported during the studies

From: Development and evaluation of a new Plasmodium falciparum 3D7 blood stage malaria cell bank for use in malaria volunteer infection studies

Adverse event

3D7-V1 (N = 2) n (M)

3D7-MBE-008 (N = 2) n (M)

Systemic

 Arthralgia

2 (2)

0 (0)

 Chills

2 (3)

2 (3)

 Decreased appetite

1 (1)

1 (1)

 Fatigue

1 (2)

0 (0)

 Feeling hot

1 (1)

1 (1)

 Headache

2 (3)

2 (3)

 Lethargy

0 (0)

1 (1)

 Malaise

1 (1)

0 (0)

 Myalgia

2 (3)

2 (4)

 Pyrexia

2 (2)

2 (3)

 Sweating

2 (2)

1 (3)

 Tachycardia

1 (1)

1 (2)

Laboratory abnormalities

 ALT increased

1 (1)

1 (1)

 AST increased

0 (0)

1 (1)

 Lymphocyte count decreased

1 (1)

2 (1)

 Neutrophil count decreased

0 (0)

1 (1)

Gastrointestinal

 Abdominal pain

0 (0)

2 (2)

 Constipation

0 (0)

1 (1)

 Diarrhoea

0 (0)

2 (2)

Other

 Back pain

0 (0)

1 (1)

 Erythema (from tape)

0 (0)

1 (1)

 Pain (venepuncture site)

0 (0)

1 (1)

 Ulcer (lip)

0 (0)

1 (1)

 Upper respiratory tract infection

1 (1)

0 (0)

  1. N, total number of participants in each cohort; n, number of participants reporting the adverse event; M, number of occurrences of adverse events. Adverse events were coded to System Organ Class and Preferred Term using MedDRA Version 20.1